Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly’s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.

Read More »

McKesson to pay $37 million to resolve West Virginia opioid lawsuit

Drug distributor McKesson Corp. agreed to pay $37 million to resolve a lawsuit by the state of West Virginia seeking to hold the company responsible for contributing to the opioid epidemic, the state’s attorney general said.

Read More »

The obscure advisory committees at the heart of the U.S. drug pricing debate

Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.

Read More »

With a Pharma Market Free of Rebates, We Can Sell on Value Again

The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.

Read More »

Walgreens shares plunge 12 percent after ‘most difficult quarter’

Walgreens Boots Alliance Inc. shares fell 12 percent after the company cut the drug retailer’s 2019 earnings growth forecast and reported lower-than-expected quarterly profit in the face of stubbornly low generic drug prices in a crowded market.

Read More »

The Brink of the Biosimilar Revolution

Although biosimilars have not had the immediate uptake in the United States that they have had in Europe, health plans expect these products will become a staple of therapy for some diseases by 2020 – if the price is right.

Read More »

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.

Read More »

Health insurers team up with IBM on blockchain project

A group of health insurers, including CVS Health Corp.’s Aetna, have teamed up with IBM Corp. to create a blockchain network aimed at cutting costs in the healthcare industry.

Read More »

CVS unveils ‘Beauty Marks’ in stores, warning shoppers of edited images

CVS Pharmacy unveiled an initiative in U.S. stores, labeling photos of models in the drugstore chain’s beauty aisles to make it clear whether the images had been digitally altered.

Read More »

Clinical Trial Finds Formula in Merix Pharmaceutical’s RELEEV 1 Day Cold Sore Highly Active Against Herpes

Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom